Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer
This article summarized the progress in diagnosis and treatment of HER2-positive NSCLC, so as to provide reference for subsequent researches.
DOI: 10.3779/j.issn.1009-3419.2023.102.14 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - April 20, 2023 Category: Cancer & Oncology Source Type: research
Early Onset Pulmonary Events and Management Strategies during the Treatment of
ALK Positive NSCLC Patients with Brigatinib
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase and its rearrangements occur in non-small cell lung cancer (NSCLC), resulting in signal dysregulation in kinase domain. As a new generation of potent ALK tyrosine kinase inhibitors (TKIs), Brigatinib was approved in China in March 2022 as a treatment for locally advanced or metastatic NSCLC patients with ALK rearrangement positive. Brigatinib significantly improved the survival, cranial efficacy and quality of life compared to Crizotinib in clinical trials. Brigatinib is generally well tolerated. Brigatinib has been one of the preferred treatments and an additi...
Source: Chinese Journal of Lung Cancer - April 20, 2023 Category: Cancer & Oncology Source Type: research
Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy
Conclusion SBRT is effective in treating early-stage NSCLC. KPS greater than 80 is an independent prognostic fa ctor for LC; BED10 greater than 132 Gy is an independent prognostic factor for OS; BED10 greater than 150 Gy is an independent prognostic factor for DMFS.
DOI: 10.3779/j.issn.1009-3419.2023.102.13 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - April 20, 2023 Category: Cancer & Oncology Source Type: research
Growth Regularity of Pulmonary Ground Glass Nodules Based on 3D Reconstruction Technology
Background and objective Since the popularization of computed tomography (CT) technology, the detection rate of pulmonary ground glass nodules (GGNs) with imaging follow-up as the main management method has increased significantly. The purpose of this study is to quantitatively analyze the changes of pulmonary GGNs during the follow-up process with three-dimensional reconstruction technology, explore the natural progression of pulmonary GGNs, and provide effective basis for clinical guidance for patients to conduct reasonable management of nodules. Methods A total of 115 cases of pulmonary GGNs with regular follow-up in th...
Source: Chinese Journal of Lung Cancer - April 20, 2023 Category: Cancer & Oncology Source Type: research
A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients
Conclusion In real-world settings, irAEs in lung cancer patients were commonly observed, with pneumonitis as the most common fatal irAEs. In addition, patients who presented any irAEs may tend to achieve a longer PFS.
DOI: 10.3779/j.issn.1009-3419.2023.101.08 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - April 20, 2023 Category: Cancer & Oncology Source Type: research
Expert Consensus on Prevention and Treatment of COVID-19 Infection in Patients with Lung Cancer
Corona virus disease 2019 (COVID-19) infection has become a major public health issue affecting human health. The main goal of epidemic prevention and control at the current stage in China is to “protect people’s health and prevent severe cases”. Patients with lung cancer who receive antitumor therapy have low immunity, and the risk of severe illness and death once infected is much higher than healthy people, so they are vulnerable to COVID-19 infection. At present, less attention has been paid to the prevention and treatment of COVID-19 infection in patients with lung cancer in domestic guidelines and consensus. Bas...
Source: Chinese Journal of Lung Cancer - April 10, 2023 Category: Cancer & Oncology Source Type: research
Current Treatment Status and Prospect of Surgery and Thermal Ablation for
Pulmonary Oligometastases in Non-small Cell Lung Cancer
Oligometastasis can be regarded as a transition state between early metastasis and extensive metastasis (limited tumor load, unique tumor biological behavior). Due to the relatively limited number of metastatic foci and the number of affected organs, there is a potential chance of cure after active systemic and local treatment. With the rapid development of molecular targeted drug therapy and immunotherapy, local therapy for oligometastatic non-small cell lung cancer (NSCLC), including oligorecurrence and oligoprogression, has received increasing attention. In this paper, the relevant research, efficacy, influencing factor...
Source: Chinese Journal of Lung Cancer - March 20, 2023 Category: Cancer & Oncology Source Type: research
Influencing Factors and Significance of Tumor-associated Macrophage Polarization
in Tumor Microenvironment
Tumor-associated macrophages (TAMs), characterized by high plasticity, are the most abundant immune cells in the tumor microenvironment (TME). TAMs are recruited to tumor region in response to various TME components such as cytokines, chemokines as well as exosomes. Subsequently, these environmental cues induce a certain polarization state of TAMs, ranging from anti-tumor states (M1-like) to pro-tumor states (M2-like). Furthermore, the polarization process of TAMs is continuous and gradually inclines toward the M2-like state with malignant progression, forming a positive feedback loop that facilitates tumor growth and meta...
Source: Chinese Journal of Lung Cancer - March 20, 2023 Category: Cancer & Oncology Source Type: research
A Real-world Study on the Expression Characteristics of PD-L1 in Patients
with Advanced EGFR Positive NSCLC and Its Relationship with the
Therapeutic Efficacy of EGFR-TKIs
Background and objective Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the first choice for first-line treatment of advanced patients with EGFR positive non-small cell lung cancer (NSCLC). For advanced NSCLC patients with negative drive gene and positive programmed cell death ligand 1 (PD-L1) or highly expressed NSCLC patients, the first-line treatment recommends immune checkpoint inhibitors (ICIs) monotherapy or ICIs combined chemotherapy. Therefore, the first-line treatment strategy for advanced NSCLC patients with EGFR positive at different PD-L1 expression levels is worth further exploring....
Source: Chinese Journal of Lung Cancer - March 20, 2023 Category: Cancer & Oncology Source Type: research
Correlation between Immune Microenvironment Features and EGFR Mutation Status
in Lung Adenocarcinoma
Conclusion EGFR-mutated lung adenocarcinoma had a unique " non-inflammatory " tumor microenvironment with low infiltration of immune cells, and there was also heterogeneity in the tumor microenvironment among the tumors with different mutation subtypes and mutation abundance. These differences were not only reflected in the number but also the spatial distribution of immune cell infiltration. Hence, further studies on the immune microenvironment of EGFR-mutant lung adenocarcinoma were of great significance for improving the efficacy of immunotherapy in EGFR-mutant lung adenocarcinoma patients in the future.
DOI: 10.377...
Source: Chinese Journal of Lung Cancer - March 20, 2023 Category: Cancer & Oncology Source Type: research
Development of A Nomogram for Predicting Survival of Patients
with Primary Mediastinal Germ Cell Tumor Based on SEER Database
Conclusion Patients with histological classification of seminoma in PMGCT have a better prognosis than patients with non-seminoma. The prognosis of patients with over the age of 40 yr, tumor size ≥15 cm and without surgical treatment was even worse. The nomogram model can accurately and intuitively predict the DSS of patients with PMGCT.
DOI: 10.3779/j.issn.1009-3419.2023.102.11 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - March 20, 2023 Category: Cancer & Oncology Source Type: research
Consensus of Chinese Experts on Nursing of Lung Cancer in the Elderly (2022 Edition)
In view of the limited data from the current prospective studies on the treatment of elderly patients with lung cancer, while drawing on The expert consensus of accelerated rehabilitation nursing in peri-operative period of lung operation in the elderly, the nursing care of the aged patients with lung cancer still needs to be concerned about radiotherapy, chemotherapy and immuno-targeted therapy. To this end, Lung Cancer Specialty Committee of Chinese Elderly Health Care Association organized a national team of thoracic medical and nursing experts, based on the latest research progress and the best clinical evidence at hom...
Source: Chinese Journal of Lung Cancer - March 20, 2023 Category: Cancer & Oncology Source Type: research
Consensus of Chinese Experts on Surgical Treatment of Lung Cancer in the Elderly
(2022 Edition)
Lung cancer ranked the highest incidence rate and mortality among people over 60 years old in China. With the increasing social population and incidence of lung cancer, the treatment of elderly lung cancer patients has become a major concern. Due to the improvement of surgical techniques and the application of enhanced recovery after surgery in thoracic surgery, more elderly patients could tolerate surgical treatment. At the same time, with the improvement of health awareness and the popularization of early diagnosis and screening, more lung cancer can be detected at the early stage. However, considering the organ dysfunct...
Source: Chinese Journal of Lung Cancer - March 3, 2023 Category: Cancer & Oncology Source Type: research
Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review
In conclusion, Aumolertinib combined with Bevacizumab in the treatment of advanced NSCLC with primary EGFR T790M mutation has a high objective response rate (ORR) and control ability of intracranial lesions, which can be used as one of the initial options for first-line advanced NSCLC with primary EGFR T790M mutation.
DOI: 10.3779/j.issn.1009-3419.2023.101.04 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - February 20, 2023 Category: Cancer & Oncology Source Type: research
Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
Lung cancer has become one of the most dangerous cancers to human health and the mortality rate is the highest among all the causes of cancer death. Non-small cell lung cancer (NSCLC) accounts for about 80%-85% of lung cancer. Chemotherapy is the main treatment for advanced NSCLC, but the 5-year survival rate is low. Epidermal growth factor receptor (EGFR) mutations are the most common driver mutations in lung cancer, but EGFR exon 20 insertions (EGFR ex20ins) mutation belongs to one of the rare mutations, accounting for about 4%-10% of overall EGFR mutations, thus around 1.8% of advanced NSCLC patients. In recent years, t...
Source: Chinese Journal of Lung Cancer - February 20, 2023 Category: Cancer & Oncology Source Type: research
